Dropprint Genomics develops software for analyzing individual cell activity in genomic data, serving researchers in immunology and drug discovery. The company reduces the cost and computational complexity of single-cell sequencing and maintains a database of over 1 million immune cells to support target identification using machine learning models.
Founders & leadership· Y Combinator alumni (W20)
Investors · 1
In the news
- AstraZeneca extends AI immuno-oncology R&D pact with Immunaifiercebiotech.com · 2024
- Company - Immunaiimmunai.com · 2022
- BioCentury - Oct. 27 Quick Takes: Advancing ‘atlas’ of immunology, Immunai raises $215Mbiocentury.com · 2021
- Immunai Using Acquisition, Funding to Shift Into Functional Work | GenomeWebgenomeweb.com · 2021
- Immunai Acquires Dropprint Genomics | GenomeWebgenomeweb.com · 2021